CASE REPORT article
Front. Immunol.
Sec. Autoimmune and Autoinflammatory Disorders: Autoinflammatory Disorders
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1651517
This article is part of the Research TopicBiologics and Targeted Therapies for Autoimmune and Auto-inflammatory Dermatoses: Balancing Efficacy with Safety and ToxicityView all articles
Misfortunes Never Come Alone: Melanoma and Ulcerative Colitis After Biologic Therapy in a Psoriatic Patient -A Case Report and Literature Review
Provisionally accepted
Aleksandra Wiktoria Bratborska1,2*
Magdalena Jałowska3
Monika Bowszyc-Dmochowska4
Michal J. Kowalczyk1Kinga Adamska3- 1Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznań, Poland
- 2Doctoral School, Poznan University of Medical Sciences, Poznan, Poland
- 3Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
- 4Cutaneous Histopathology and Immunopathology Section, Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Psoriasis affects approximately 2% of the global population, with plaque psoriasis being its most prevalent manifestation. Management strategies range from topical therapies for mild cases to systemic interventions for moderate to severe cases. Those include immunosuppressive drugs and biological agents, which are novel therapeutic options that have revolutionized psoriasis management. Patients with psoriasis have a higher risk of developing other autoinflammatory diseases, as well as cancer. In addition, both classic immunosuppressive agents and biologics carry a risk of malignancies. We present a case of a 36-year-old male with a long history of plaque psoriasis and psoriatic arthritis. He was undergoing treatment with secukinumab and also had a history of therapy with infliximab. During the treatment course, the patient noted a progressively enlarging pigmented lesion on his left calf, which was subsequently diagnosed as superficial spreading melanoma. Following this diagnosis, he was informed about the potential oncological risks associated with biological therapy and switched to acitretin and methotrexate. Over two years later, he was diagnosed with ulcerative colitis (UC) after endoscopic evaluation. No melanoma recurrence has been observed to date. Our case report demonstrates the difficulties in managing malignancies in patients receiving biologic therapy, highlighting the necessity for careful medical assessment and examination of patients receiving those types of drugs. In cases of cancer coexistence, a multidisciplinary approach is crucial for the sufficient treatment of both oncological and
Keywords: Psoriasis, biologics, biologic therapy, targeted therapy, Skin inflammation, autoinflammatory skin diseases, Autoinflammatory dermatoses
Received: 21 Jun 2025; Accepted: 11 Aug 2025.
Copyright: © 2025 Bratborska, Jałowska, Bowszyc-Dmochowska, Kowalczyk and Adamska. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Aleksandra Wiktoria Bratborska, Department of Dermatology and Venereology, Poznan University of Medical Sciences, Poznań, Poland
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.